Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Foresee Pharmaceuticals to Present at the American Heart Association Annual Meeting Focusing on its ALDH2 activator FP-045 in Pulmonary Hypertension Associated with Interstitial Lung Disease 2023-10-30 15:18
Foresee Pharmaceuticals Selected for Late-Breaking Oral Presentation on its Aderamastat Phase 2 Study Results at the European Respiratory Society (ERS) International Congress 2023 2023-07-25 15:19
Bassem Elmankabadi, M.D. joins Foresee Pharmaceuticals as a Senior Vice President of Clinical Development 2023-04-17 16:50
Foresee Pharmaceuticals and TRPharm Announce License and Co-Development Agreement 2022-02-23 23:00
Foresee Pharmaceuticals Announces FDA Approval of CAMCEVI® for the Treatment of Advanced Prostate Cancer; Accord BioPharma to Head the U.S. Commercialization 2021-05-27 11:33
Foresee Pharmaceuticals Announces Dosing of First Patient in Phase 2/3 Clinical Trial of FP-025 for Treatment of COVID-19 Associated ARDS 2021-03-28 11:04
Foresee Pharmaceuticals Enters Exclusive License Agreement with Intas Pharmaceuticals for Commercialization in the United States 2021-03-04 23:00
Foresee Pharmaceuticals Announces Completion of US$47 Million Financing 2020-12-24 18:00
Foresee Pharmaceuticals Enters Exclusive License Agreement with GenSci for the Commercialization of Camcevi(TM) in China 2020-11-17 17:51
Foresee Pharmaceuticals Announces NDA for CAMCEVI(TM) 42MG Accepted for Review by the FDA 2020-10-09 06:39
Foresee Pharmaceuticals Announces Submission of NDA for FDA Approval of LMIS 50 mg 2020-07-28 12:34
Foresee Pharmaceuticals and Accord Healthcare Announce MAA Submission for Camcevi(R) 42mg 2020-03-27 19:53
Foresee Pharmaceuticals Announces Submission of NDA for FDA Approval of LMIS 50 mg 2019-03-30 04:06
Foresee Pharmaceuticals Announces Successful Topline Results from Phase 3 Registration Study of LMIS 25 mg in Prostate Cancer 2019-02-21 18:30
Foresee Pharmaceuticals Enters Exclusive License Agreement with Accord Healthcare 2019-02-11 18:30
Foresee Pharmaceuticals Announces Sr. VP of Pharmaceutics and Manufacturing Appointment 2018-11-15 20:33
Foresee Pharmaceuticals Announces Results from a Phase 1 Clinical Study, Highlighting Promising Safety, Tolerability and Pharmacokinetic Profile of FP-045, a Potent ALDH2 Activator 2018-07-26 19:30
Foresee Pharmaceuticals and Megapharm Announce License and Distribution Agreement 2018-01-03 20:02
Foresee Pharmaceuticals and TRPharm Announce License and Distribution Agreement 2017-09-27 19:56
Foresee Pharmaceuticals Announces CEO Appointment 2017-07-31 18:53
1